(CercleFinance.com) – LNA Santé loses nearly 4% in Paris, penalized by an analysis by Oddo which maintains its ‘neutral’ recommendation on the share with a price target lowered from 55 to 42 euros, taking into account its new projections and the drop in comparables.
“We regret that LNA Santé presents a 2022 profit profile of moderate growth (consolidation of margins), because for us, LNA could stand out and could have presented more upside, in this context of crisis”, affirms the analyst.
Oddo BHF considers in particular that LNA Santé appears to him to be ‘comparatively very virtuous in terms of medical and ethical practices’, and that it is ‘pursuing a disciplined strategy of regular and balanced growth (between acquisition and organic)’.